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Abstract 
Chronic pain constitutes a challenge for the scientific community and a significant economic and social cost for 
modern societies. Given the failure of current drugs to effectively treat chronic pain, which are based on suppressing 
aberrant neuronal excitability, we propose in this review an integrated approach that views pain not solely originating 
from neuronal activation but also the result of a complex interaction between the nervous, immune, and endocrine 
systems. Pain assessment must also extend beyond measures of behavioural responses to noxious stimuli to a more 
developmentally informed assessment given the significant plasticity of the nociceptive system during the neonatal 
period. Finally integrating the concept of perinatal programming into the pain management field is a necessary step 
to develop and target interventions to reduce the suffering associated with chronic pain. We present clinical and ani-
mal findings from our laboratory (and others) demonstrating the importance of the microbial and relational environ-
ment in programming pain responsiveness later in life via action on hypothalamo-pituitary adrenal (HPA) axis activity, 
peripheral and central immune system, spinal and supraspinal mechanisms, and the autonomic nervous system.
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Background
Physiological pain plays an essential and primordial func-
tion in our survival. It signals potential damage to the 
body and produces a wide range of sophisticated actions 
to prevent this damage. The perception of noxious stimuli 
is typically initiated by the activation of peripheral recep-
tors (i.e. nociceptors) which signal the spinal dorsal horn 
and supraspinal neurons of any potentially tissue-damag-
ing stimuli. In pathological conditions, however, failure 
to sense pain such as in the case of congenital insensi-
tivity often lead to self mutilation, bone fractures, joint 
deformities, amputations, and even early death, under-
scoring the importance of the physiological, protective 
role of nociceptive pain [1]. Chronic pain, the unbear-
able pain that persists long after an injury has healed, can 
drive the individual to immobility, psychological distress, 
depression, and disruption of family relationships, and 
potentially loss of employment. Chronic pain is common 
in developed countries. Prevalence rates of 16–22 % have 
been reported from epidemiological surveys [2–4]. One 
recent study lists chronic back pain (along with depres-
sion) in the top 10 causes of morbidity in over 180 coun-
tries [5]. Chronic pain incurs a multi-billion dollar cost to 
most developed western countries [6, 7]. Despite mount-
ing evidence regarding the complexity of the nature of 
chronic pain there remains a general resistance [8] to 
the understanding that the nature of chronic pain is not 
primarily a matter of nociception (i.e. a noxious stimulus 
generating neural impulse), despite ample evidence of the 
multidimensional nature of chronic pain [9].
Pharmaceutical treatments, still our primary treatment 
modality, have a 25–30  % placebo rate, making thera-
peutic benefits difficult to establish. Some of the drugs 
such as the use of opioids (i.e. morphine), which can act 
on opioid-receptor-expressing neurons in brain areas 
that control pain (i.e. PAG) are effective but have a very 
narrow therapeutic window and in most of the time the 
dose needs to be limited to avoid side effects or analgesic 
tolerance which occurs upon repeated administration of 
opioids requiring increased dosage to maintain satisfac-
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still a stubborn condition? What are the limitations of the 
current therapeutic approaches? Are we understanding 
and managing pain in its full complexity?
While our understanding of the complex mechanisms 
involved in the development and maintenance of chronic 
pain has increased dramatically in recent decades, treat-
ments in various modalities continue to be based on a 
reductionist approach that understanding the precise 
nociceptive mechanisms that cause pain, will result in 
more targeted and hence more effective treatments. 
Given the myriad of neuroimmunoendocrine links now 
understood to modulate chronic pain, focusing on tar-
geted specific mechanisms may be missing the bigger 
picture. Furthermore, given that pain has also a cognitive, 
aversive component there is a need to target the cogni-
tive/emotional aspect of pain not only the sensory dis-
criminative component.
From Galen to the gate-control theory developed 
by Melzack and Wall, pain has been viewed either as a 
separate, independent sensation, an emotion, or a result 
from activation of nociceptors, spinal and supraspinal 
pathways. This review proposes a shift in conceptualising 
the problem of chronic pain away from a dichotomous 
standpoint to an integrative view which captures both 
the sensory and the emotional-cognitive in a framework 
that emphasises the neuroendocrine to immune commu-
nication pathways and the relevance of early premorbid 
events as predictors.
Specifically we focus on the early life environment 
and its ability to program the organism’s physiological, 
affective and behavioural responses in later life [10–14]. 
Almost invariably, randomised control trials (RCTs) com-
mence their assessment of pain by assessing the baseline 
values from the time the pain started. There is an implicit 
assumption, that prior to the onset of pain, “patients” 
are physiologically naïve and functionally equivalent—
though there is some acknowledgement that their psy-
chosocial history may differ. The thesis proposed here 
is that a neurodevelopmental understanding is required 
to account for the individual variability in response to 
the initiating noxious insult/stimulus as well as to sub-
sequent treatments. We argue that not taking account 
of the premorbid physiological milieu may be limiting 
efforts to develop more tailored and more effective treat-
ment interventions. In short, chronic pain patients may 
be differentially predisposed to recovering (or not recov-
ering) from a physical injury, infection or trauma because 
of their premorbid psychoneuroimmunological status.
The traditional theory of pain
A brief historical overview
Aristotle (384–322 BC) considered pain to be an emo-
tion. Later the Greek physician Galen (AD 130–201) 
using the experimental scientific method disagreed 
with Aristotle’s view and considered pain to be a sensa-
tion and the brain an organ for feeling. Avicenna (AD 
980–1037) a renowned Persian philosopher, who is con-
sidered the father of modern medicine, argued that pain 
can be dissociated from touch. During the mid-1900s 
several studies performed by imminent Scottish and 
English neurologists demonstrated that hemi-section of 
the spinal cord resulted in a loss of pain sensation. The 
work by Blix and Goldcheider in 1884 and of Von Frey 
in 1897 demonstrated that different sensory experiences 
(i.e. pressure, cold, heat, pain) evoke the activation of dif-
ferent nerve endings. The terms noxious and nociception 
appears with Sherrington in 1906 who considered that 
noxious or painful events result in the activation of sense 
organs and this in turn produces pain [15]. In the 1930s, 
several studies by Bishop and Gasser demonstrated that 
noxious sensations are conveyed by two types of nerve 
fibers, namely Aδ and C [16]. It was with the develop-
ment of the gate-control theory by Ronald Melzack and 
Patrick Wall in 1965 that the representation of pain as a 
unidirectional pathway from the site of injury to the sen-
sation of pain was challenged. Instead pain was viewed 
as a result of supraspinal (brain) activity [17]. The devel-
opment of new imaging techniques such as positron 
emission tomography (PET) and functional magnetic 
resonance imaging (fMRI) have revealed that pain results 
from activation of a number of brain regions such as the 
amygdala, insula or the anterior cingulate cortex.
Taken together, this brief historical outline illustrates 
the classical view that pain is an independent sensation, 
an emotion, a product of activation of nociceptors or spi-
nal and supraspinal pathways. More recent conceptuali-
sations of pain now view pain as a result of the complex 
interaction between the immune, nervous (both CNS 
and autonomic nervous system), and endocrine systems. 
Furthermore, a number of studies including findings 
from our laboratory clearly demonstrated that exposure 
to early life insults such as hindpaw inflammation, psy-
chological/emotional or physical stress, as well as viral/
bacterial infection can all lead to altered future pain 
responses [10, 18–24].
Overview of chronic pain
Chronic pain described as a continuing (unremitting) 
presence for periods longer than 3–6  months, has been 
defined as: “an unpleasant sensory and emotional experi-
ence associated with actual or potential tissue damage or 
described in terms of such damage” by the International 
Association of for the Study of Pain (IASP).
Our current understanding of chronic pain is that it 
falls into one of 4 categories—nociceptive, neuropathic, 
psychogenic or a combination of these. Nociceptive 
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pain arises from tissue injury, which activates nocicep-
tors (pain receptors) in the periphery that send signals 
to the central nervous system (CNS). Nociceptive pain 
can be inflammatory or musculoskeletal in origin. Neu-
ropathic pain, arises from damage to nerves that results 
in an altered quality (e.g. sharp, burning) and intensity of 
pain signals. However in clinical practice, these divisions 
are not easily discriminated from each other and often 
overlap. Nevertheless, the diagnostic divisions assist with 
directing therapeutic options.
Indicative of the complexity of chronic pain is the phe-
nomenon of sensitization. There are two types of sensi-
tization. The first type refers to peripheral sensitization 
which occurs in response to the release of a plethora 
of inflammatory molecules such as histamine, prosta-
glandins, pro-inflammatory cytokines which sensitizes 
(or increase the excitability) of nociceptors by creating 
an “inflammatory soup” environment which enhances 
pain sensitivity by reducing the threshold of nocicep-
tors activation. The second type is central sensitization 
which refers to exacerbation of pain sensation and can be 
caused by hyperexcitability of spinal dorsal horn neurons 
or a decrease in inhibition of spinal dorsal horn neurons. 
The two phenomena of hyperalgesia (an exaggerated 
response to a normally painful stimulus) and allodynia 
(an exaggerated response to a normally non-painful 
stimulus) are clinical markers used to detect the presence 
of sensitization. There is now accumulating evidence 
that chronic pain sensitivity is elevated across different 
modes (e.g. pressure, thermal, pricking) within chronic 
pain populations. This has led to the use of quantitative 
sensory testing (QST), that attempts to measure pain 
related parameters such as pain thresholds, temporal 
summation and pain duration using repeated stimuli in 
multiple locations on the body and with multiple modali-
ties (e.g. thermal, chemical, mechanical) [25]. So to illus-
trate, pain threshold can be evaluated by measuring the 
time taken for the person to report the sensation of pain 
once a graduated stimulus (e.g. temperature/pressure) is 
applied.
DNIC (one type of QST) is considered to be a marker 
of endogenous (possibly opioid) analgesia, and reflects 
the capacity of the CNS to modulate (down-regulate) 
nociceptive signals [25]. DNIC comprises the inhibi-
tion of a nociceptive test stimulus when a distant, usu-
ally contralateral noxious conditioning stimulus has been 
pre-emptively applied. In other words the first pain-
ful stimulus “dulls” the intensity of the second (“test”) 
stimulus. This reduction in intensity of the second test 
stimulus, is understood to be mediated by bi-directional 
opioid-sensitive neurons in the spinal-medullary-spinal 
pathway [26]. This capacity has been found to be reduced 
in a range of idiopathic pain related conditions such as 
tempero-mandibular disorders, fibromyalgia, tension 
head-ache, migraine and irritable bowel syndrome [26] as 
well as in a healthy non-patient population [27].
However attention is drawn to the predictive capacity 
of DNIC in post-surgical pain, which suggests that at least 
part of the pain response is determined by physiological 
factors that precede the onset of pain. The significance 
of this should not be overlooked, as this observation 
suggests that pre-existing vulnerability to cope with the 
surgical-related trauma. Consistent with this line of evi-
dence, are recent observations from imaging studies that 
indicate that functional connectivity between the medial 
prefrontal cortex, (mPFC), and nucleus accumbens, 
(NAc) are also predictive of those who progress from 
sub-acute (<4  months) to chronic (>6  months) lower 
back pain [28, 29]. Again note that the altered connec-
tivity precedes the onset of acute pain, again implicating 
premorbid factors involved in the transition from (sub) 
acute to chronic pain. There has been a long-standing 
debate whether the features of chronic pain populations 
(e.g. demographics, education, gender, depression, sleep-
lessness, not coping, fear of pain, catastrophization, job 
satisfaction, helplessness) explain the acute to chronic 
pain transition. While these factors collectively account 
for 25 % of pain CP intensity, and 33 % of total disabil-
ity [30], it is notable that for chronic back pain, the most 
common site of pain [2, 3], there are cognitive-emotional 
cortical regions that account for 70–80  % of the vari-
ance of pain intensity and duration [31]. In other words, 
higher order processing (including of emotional ele-
ments) appears to be more salient in the transition to and 
maintenance of chronic pain than is commonly appreci-
ated. It is therefore of concern when treatment of chronic 
(low-back) pain is primarily focused on linking structural 
and mechanical causes (that predict only 17 % of the pain 
intensity variance and is unrelated to disability [31], to 
behavioural manifestations of the pain. This may be more 
easily remembered by the phrase—‘the gain in the pain 
happens mainly in the brain’.
Pain pathways
The conventional, traditional anatomical circuit of pain 
starts with the activation of nociceptors by multimodal 
noxious stimuli (i.e. thermal, physical, or chemical). 
There are two major classes of nociceptors. The first 
class includes thinly myelinated Aδ that are responsible 
for detecting well localized sharp, fast pain (speed of 
conduction: 5–30 m/s). The second category or C-fibers 
(unmyelinated; velocity less than 1  m/s) and belong to 
primary sensory neurons whose cell bodies are present 
in the dorsal root ganglia for the body or the trigemi-
nal ganglion when innervating the face. Most Aδ fibres 
respond to heat as well as mechanical stimuli, whereas 
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most C fibres are polymodal and respond to noxious 
thermal, mechanical, and chemical stimuli. Moreover, 
there are two main groups of C fibres: those that express 
the P2X3 purine receptor, the IB4-lectin-binding site 
and receptors for Glial Cell Derived Neurotrophic Fac-
tor (GDNF). This first group of fibres project exclu-
sively to lamina II. The second group expresses peptides 
such as substance P and calcitonin gene related pep-
tide (CGRP), but also expresses the receptor for nerve 
growth factor (NGF), neurotrophic tyrosine kinase 
receptor type 1 (TrkA). This group projects mainly to 
Lamina I. When activated, these peptidergic C fibres 
induce plasma extravasation and vasodilatation [30]. 
Many of the neurons in the marginal layer (Lamina I) 
respond exclusively to noxious stimuli and are called 
“nociceptive-specific neurons”, whereas some neurons 
respond to both noxious and non-noxious stimuli and 
are called “wide dynamic range” neurons. The substantia 
gelatinosa or Lamina II is made up exclusively of excita-
tory (glutamate) and inhibitory (gamma aminobutyric 
acid, GABA) interneurons. The nociceptive message, 
after being detected by peripheral nerves, is conveyed to 
neurons in the spinal cord that cross the spinothalamic 
tract (see Fig.  1) and make synapses in the thalamus. 
Once the message arrives at the somatosensory cortex, 
the conscious perception of pain occurs. The sensori-
discriminative component of pain is integrated in the 
somatosensory cortex, whereas the emotional-affective 
component is coded by limbic structures such as the 
anterior cingulate cortex, amygdala, and insular cortex 
[31]. Other ascending pathways exist for the transmis-
sion of pain such as the one that initiates in the spinal 
cord and projects to the parabrachial nucleus, and then 
to the hypothalamus and amygdala; or the spinoreticu-
lar pathway that crosses the reticular formation in the 
medulla level, then thalamus and finally reaches the 
postcentral gyrus. In addition to these ascending path-
ways, the control of pain involves descending pathways 
also known as inhibitory descending control systems.
Figure 1 illustrates the complexity of the processing, as 
indicated by the number of tracts and regions involved. 
It would seem evident that there is no single anatomi-
cal region in the CNS that registers and processes noci-
ception. This complexity would suggest processing far 
beyond that of mere auditing pain intensity and location. 
Also the involvement of the hypothalamus, thalamus, LC 
and parabrachial regions raises the possibility that all 3 
stress-related neuroendocrine pathways listed above, 
being activated by pain. Finally activation of the prefron-
tal cortex (medial and lateral), the cingulate gyrus and 
insula cortex raises the distinct likelihood that higher 
order cognitive and emotional elements are involved with 
the processing of nociceptive stimuli.
In addition, recent studies using magnetic resonance 
spectroscopy have shown that there are differences in 
the neural processing between experimental pain within 
control subjects, and chronic pain in clinical populations. 
Afferent nociceptive information (via the thalamus) 
which projects to the somatosensory, insular and ante-
rior cingulate cortices is more prominent in experimental 
pain conditions; by contrast projection to the prefrontal 
cortex (possibly via spinohypothalamic, spinoparabra-
chial and spinoreticular pathways) is more evident in 
chronic pain conditions [32]. Of note is that the pre-
frontal cortex (and thalamus) is associated with signifi-
cant loss of grey matter in chronic back-pain patients 
[33]. What appears to be increasingly recognized is the 
importance of higher order processing of the nocicep-















Fig. 1 Anatomy of the pain pathways. Primary afferent nocicep-
tors convey noxious information to neurons within the spinal dorsal 
horn of the spinal cord. These neurons project to the thalamus via 
the spinothalamic pathway and then to somatosensory cortex. This 
projection provides information about the location and nature of the 
stimulus (pathway in blue). The affective component is provided by 
projections to the cingulate and insular cortices via projections in the 
brainstem (parabrachial nucleus) and amygdala (pathway in orange). 
Descending inhibitory control pathways (Red line) originating in the 
PAG and RVM in the brainstem control the output of spinal nocicep-
tive neurons in response to a noxious stimulus. PAG periaqueductal 
grey, PB parabrachial nucleus, RVM rostroventral medulla, DRG dorsal 
root ganglia
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conditions that have a pervasive and enduring impact 
upon the same higher order processing regions, prior to 
the onset of chronic pain. Childhood psychosocial stress-
ors have such an impact upon adult neuroendocrine 
functioning and have been associated with the presence 
of chronic pain [37–42].
Why pain treatment is ineffective?
Sixty-plus years of intensive research in the pain field 
have led to the discovery of countless drugs includ-
ing aspirin and pioneer findings such as the induction 
of analgesia by direct stimulating of the periaqueductal 
grey (PAG) in rodents [43] and humans [44]. Opioids are 
effective in attenuating the noxious stimulus. These mol-
ecules (whether endogenous or exogenous) exert their 
action through activation of opioid receptors which are μ, 
δ (DOR/OPDR), κ (KOR/OPRK1), and opioid-like recep-
tors (ORL1/OPRL) [45] that are expressed peripherally 
by leukocytes or by primary sensory neurons but also 
can be expressed centrally in key nuclei involved in the 
descending pain inhibitory pathways such as PAG and 
rostroventral medulla (RVM). However the use of opioids 
in modulating pain has a downside, they can be addictive 
and enhance alcohol consumption. They can also induce 
opioid tolerance where repeated exposure to opioids 
decreases drug efficacy over time. The use of slow-release 
drug patches, local anaesthetics, or spinal epidurals, 
which can act either by blocking the transmission of nox-
ious input to the brain or by attenuating the excitability 
of spinal and supraspinal neurons have brought relief to 
some patients but not all. Surprisingly drugs that were 
traditionally prescribed to control depression were shown 
to be effective in treating chronic pain and the same dis-
covery applied for drugs that were originally designed to 
treat epilepsy and were found to relieve severe chronic 
pain. These drugs shifted the focus onto the brain. How-
ever despite the effectiveness of these drugs, treating 
chronic pain is still challenging for clinicians. We argue 
that one of the reasons resulting from this challenge is 
the complexity of the interaction between multiple physi-
ological systems that modulate pain as well as the role of 
early life events in programming pain responses later in 
life. Early life exposure to adverse events whether it is of 
psychological, physiological, bacterial or viral nature has 
been shown to exert programming effects on the hypo-
thalamus–pituitary–adrenal axis [10, 46–48], a key sys-
tem that modulates the stress response to physiological 
or psychological stressor. Given that pain is an aversive, 
stressful experience, these early adverse events are also 
capable of altering future pain responses through action 
on the endocrine system. Below we present clinical and 
animal evidence that demonstrate the impact of early life 
insult on neuroendocrine and pain responses.
Perinatal exposure to adverse events alter the 
hypothalamus–pituitary–adrenal (HPA) axis later 
in life
The experience of stress, from an evolutionary per-
spective, plays a pivotal role in promoting survival of 
the organism. Perceiving an environmental stimulus as 
threatening and learning to avoid it is essential for sur-
vival. The HPA axis is the major neuroendocrine media-
tor of the stress response and is known to be susceptible 
to perinatal programming [49, 50]. The cascade of sig-
nalization in the HPA axis in response to stress begins 
with activation of a group of neurosecretory neurons in 
the paraventricular nucleus of the hypothalamus (PVN). 
These neurons secrete corticotropin-releasing hor-
mone (CRH) and to a lesser extent arginine vasopressin 
(AVP) into the portal vessel system to reach the anterior 
pituitary where the synthesis of pro-opiomelanocortin 
(POMC) takes place and then processed to adrenocorti-
cotropic hormone (ACTH) [51]. Subsequent increase in 
circulating ACTH then drives the synthesis of cortisol 
(in humans) and corticosterone (in rodents). Attenua-
tion of the magnitude of the HPA stress response occurs 
through negative feedback of glucocorticoids on gluco-
corticoid (GR) and mineralocorticoid (MR) receptors 
expressed in neurons of the hippocampus, hypothala-
mus, and pituitary. This results in a negative feedback 
loop [52, 53] and maintains homeostasis. The HPA axis 
is therefore designed to provide a quick and appropriate 
response to stress by stimulating a relatively brief influx 
of glucocorticoids into the body. Moreover, this respon-
sivity is determined, in part, by the relative affinity of glu-
cocorticoids for MRs and GRs [54]. The HPA axis goes 
through a period of significant change and development 
during the perinatal period and exposure to adverse 
events during this period is known to produce long-term 
alterations in neuroendocrine function and behavior.
Prenatal studies
Human studies
A growing body of clinical literature has demonstrated 
that exposure to stress during the perinatal period is 
linked to adverse health outcomes later in life [55–58] 
including susceptibility to developing psychiatric disor-
ders and cognitive impairments. This is of particular rel-
evance given that in modern society we are increasingly 
exposed to pollutants and stress, and thus it is proposed 
that the propensity for dysregulation of immune and 
metabolic homeostasis is rising.
The intrauterine events can have significant lasting or 
even lifelong repercussions such as cardiovascular disease 
or diabetes type 2 [59]. This delayed insult to the organism’s 
integrity is referred to as programming and is associated 
with sensitive periods during gestation. Various components 
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of the stress related system develop at different rates. For 
instance, ACTH has been detected as early as 7  weeks, 
while corticotropin-releasing hormone CRH is produced by 
the placenta and hypothalamus and appears at 12–13 weeks 
[60]. The significance of these developmental stages for 
maternal stress is still unknown, however it is clear that 
levels of maternal glucocorticoids above that required for 
normal maturation [61] can have a negative “programming” 
impact on the foetus [53, 62]. These effects include growth 
retardation, HPA dysregulation, behavioural alterations and 
glucose intolerance in the offspring. [63]. Exposure to stress 
during pregnancy has also been linked to altered endocrine 
responses later in life. Maternal anxiety, depression, or stress 
have been associated with increased basal responsivity of 
the HPA axis in the offspring of children at 6 months [64], 
5 years [65], and 10 years of age [58]. Pregnant mothers sub-
jected to psychosocial stress showed alterations in HPA axis 
activity as indicated by high level of ACTH and decreased 
serum cortisol level when compared to a prenatally non-
stressed group [66]. It has also been noted that social stress 
and lack of support during pregnancy, can increase IL-6 lev-
els, increase CRH levels and decrease IL-10 levels within the 
maternal circulation [67].
Animal studies
The HPA axis goes through a period of increased plas-
ticity during the perinatal period. Whilst GR mRNA in 
the hypothalamus can be detected as early as gestational 
day (GD) 16 [68], MR mRNA is not detected until PND 
2 [69]. Thus, exposure to stressors during this sensitive 
period of development can have long-term consequences 
on the HPA axis. Physiological levels of glucocorti-
coids play a crucial role in brain development. They are 
involved in axonal and dendritic remodeling, and can 
affect cell survival [70]. However, sustained increases 
or removal of glucocorticoids during development can 
permanently alter brain structure and function [49, 71]. 
For instance, administration of the glucocorticoid syn-
thetic Dexamethasone in pregnant rats contributed to 
delay in the maturation of neurons, myelination, glia, and 
vasculature in the offspring, leading to altered neuronal 
cytoarchitecture, altered synaptogenesis, and attenuated 
levels of neurogenesis [72]. Furthermore, adult rats pre-
natally exposed to glucocorticoids displayed increased 
CRH levels in the central nucleus of the amygdala [73], 
a key region in the regulation of the emotional compo-
nent of pain [74]. Exposure to a novel environment com-
bined with a saline injection (mild stress) from GD14 to 
GD21 is also associated with elevated plasma levels of 
ACTH and corticosterone in adulthood. Moreover when 
offspring from prenatally stressed rats were exposed to 
an acute foot shock, they exhibited a greater amount of 
shock-induced freezing time than the control group [75].
Postnatal studies
Human studies
The hippocampus is a key regulator of the stress response 
having inputs into a variety of key loci in the brain that 
regulate behavioural and endocrine responses to stress 
[76, 77]. The hippocampus represents a major regulator 
of HPA axis activity. Activation of glucocorticoid (GR) 
and mineralocorticoid (MR) receptors by circulating 
glucocorticoids (e.g. corticosterone) provides a negative 
feedback, which serves a key role in maintaining normal 
functioning of HPA axis. A number of studies have shown 
that exposure to adverse life events such as poverty [78], 
abuse [79], or orphanage rearing [80] can lead to children 
with increased stress reactivity and dysregulated HPA 
function in adulthood. For instance, in an aged human 
population, long-term exposure to endogenous levels of 
glucocorticoids resulted in memory impairments and a 
significant decrease (14  %) in hippocampal volume [81]. 
Low birth weight combined with low maternal care con-
tributed to smaller hippocampal volume in adulthood, 
leading to increased susceptibility to stress-related disor-
ders in later life [82, 83]. Maternal emotional well-being 
can also affect the development of the hippocampus in 
children. Magnetic Resonance Imaging (MRI) studies 
revealed that children from mothers who experienced 
high level of anxiety during the last trimester of preg-
nancy exhibit slower growth of both hemispheres of the 
hippocampus over the first 6 months of postnatal life [77]. 
Decreased hippocampal volume has also been associated 
with being sexually abused at 3–5 and 11–13 years of age 
[84]. Parent–child interactions and the emotional state of 
the pregnant mother are also critical factors in determin-
ing HPA axis responsivity of the child later in life. There is 
increasing evidence that children from depressed mothers 
are at higher risk of increased HPA axis activity [78].
Animal studies
In rodents, the first two postnatal weeks constitute an 
important time window for HPA axis ontogeny whereby 
the HPA axis goes through a “stress hyporesponsive 
period” (SHRP) from PND 4 to PND 14 during which 
adrenal sensitivity to stressors is diminished and corticos-
terone concentrations are maintained at low levels [85]. 
Furthermore, the maturation of hypothalamic neurocir-
cuits is not completed at birth and undergoes fine-tuning 
until the third postnatal week. Whilst the neuronal cell 
population in the hypothalamus is determined prior to 
birth, the formation of functional neuronal networks via 
axonal projections and synaptic connections occurs later 
during the postnatal period [86]. Adult rats challenged 
with LPS as neonates displayed increased CRH mRNA 
in the PVN, indicating decreased levels of negative 
feed-back and hence increased HPA axis activity [47]. 
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Maternal care constitutes a major determinant of an indi-
vidual’s development, shaping the phenotype by affecting 
brain structure and function and ultimately determining 
personality, physiology and behaviours. Maternal separa-
tion, an animal model of human child maltreatment, has 
been linked to increased density in CRH binding sites 
in the hippocampus, prefrontal cortex, amygdala, and 
hypothalamus, as measured post-infancy [48]. Daily han-
dling from PND 2 to PND 8 resulted in down-regulation 
of hypothalamic CRH mRNA levels in PND 23 rats [46]. 
Our laboratory was recently able to demonstrate that 
exposure to the bacterial mimetic LPS at PNDs 3 and 5 
can also alter HPA axis in a developmentally regulated 
way as indicated by increased circulating corticosterone 
at PNDs 7 and 22 but not 13 and decreased GR mRNA 
and increased MR mRNA in the hypothalamus of PND 
22 rats following formalin injection [10]. Similar find-
ings were reported by other researchers whereby LPS 
exposure during PNDs 3 and 5 resulted in decreased GR 
binding and density in the hippocampus, hypothalamus, 
and frontal cortex of adult rats following adrenalectomy 
[47]. Moreover, adult rats challenged with LPS as neo-
nates displayed increased CRH mRNA in the PVN, indi-
cating decreased levels of negative feed-back and hence 
increased HPA axis activity [47].
Taken together, animal and human studies suggest 
that exposure to stress during the perinatal period where 
key brain areas are still developing at the time of stress 
exposure, can have long-term consequences on HPA axis 
activity, leading to exaggerated responses to a stressful 
event encountered later in life. The effects on HPA axis 
depend on the nature of the stressor as well as the timing 
when it occurs (i.e. prenatal vs. postnatal).
Plasticity of the nociceptive system during the 
neonatal period
Nociceptive neural circuitries undergo significant 
changes during the early neonatal period, and there-
fore remain vulnerable to the effects of early insults. For 
instance, substance P, a specific marker of peptidergic 
C fibres, is present at birth suggesting the development 
of chemical properties of these fibres at an early stage. 
The peptidergic C fibers are a population of C fibers that 
release neuropeptides such as substance P and calcitonin-
gene-related-peptide (CGRP) as well as the Trk A neuro-
trophin which binds to nerve growth factor (NGF) [31]. 
In the dorsal horn, substance P fibres are concentrated in 
Lamina I on day 1; in the next few days, the density in 
Lamina II is increased and by the end of the first week 
of development, the staining of the fibers is comparable 
to the one observed in adults [87]. Moreover, the non-
peptidergic C fibres that express the IB4 isolectin can-
not be detected in the synapse until PND 5 despite their 
presence in dorsal root ganglion from embryonic day 18. 
This delay suggests that these fibres form synapses later 
than peptidergic C-fibres. Finally, both neonate A-fibres 
and C fibres express µ-opioid receptors, although this 
expression becomes restricted to C fibres by PND 21 [88].
There is a functional maturation of spinal dorsal horn 
which is also developmentally regulated. Dorsal horn 
cells in deep laminae do not respond to C fibre input until 
PNDs 7–8. Similarly, specific C-fibre-evoked reflexes 
produced by mustard oil (a chemical skin irritant) do not 
occur until rat pups reach day 10–11 [89]. The activation 
of C fibres is unable to evoke spike activity in the spinal 
cord before the second postnatal week. Aδ fibres are 
completely unmyelinated until the pups reach 2–3 weeks 
[89]. In the mature state, Aβ fibres which convey non-
noxious stimuli project into Laminae III to V [90], while 
nociceptive fibres terminate in the superficial laminae 
(Laminae I and II). However, in the immature state large 
myelinated fibres, which normally integrate non-painful 
stimuli such as touch, are found to project to Laminae 
I to V including Laminae II. In other words, fibres that 
normally convey non-noxious stimuli can integrate nox-
ious information as well. At the supraspinal level, the 
inhibitory descending control system is not apparent 
until the second postnatal week. Interestingly, electrical 
stimulation of the PAG does not produce analgesia until 
at least PND 10 [91]. Of particular interest, a recent study 
showed that there is a developmental postnatal shift in 
the brainstem rostroventral medulla (RVM) control of 
spinal dorsal horn neuronal circuits from A fibre facilita-
tion activity in young animals to inhibition of nociceptive 
C fibre input in the adult animal [92].
Taken together, these data demonstrate that the noci-
ceptive system during early life presents an important 
“window of vulnerability” during which an early insult 
such as inflammation, bacterial infection or a polymodal 
stimulus (mechanical, chemical or thermal), may result 
in the disruption of the neuronal and chemical circuitry 
modulating pain, leading to altered behavioural and neu-
ronal responses to noxious stimuli later in life.
Neonatal noxious stimuli alter future pain 
responses
Human studies
In contrast to the traditional view that argues neonates 
are unable to feel pain, it is now well acknowledged that 
neonates are neuroanatomically and functionally able to 
discriminate between noxious and innocuous stimuli as 
indicated by scalp electroencephalography and spectros-
copy studies [93, 94]. Preterm infants (<37 weeks of ges-
tation) are born during a critical period when the brain 
is still undergoing significant plasticity and development. 
Preterm infants admitted to the neonatal intensive care 
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unit (NICU) are routinely exposed to stressful and inva-
sive procedures (i.e., heel lance, chest tube insertion, tape 
removal, and nasogastric tube insertion) to maintain 
their survival [95]. These infants exhibit significant alter-
ations in sensory and pain processing later in adulthood 
[96, 97]. For instance infants subjected to repeated heel 
lance develop hyperalgesia compared to non-injured con-
trols [98]. A number of studies have demonstrated that 
exposure to such adverse events can contribute to altered 
brain neurocircuitry and processing, leading to poorer 
outcomes at school age [99–101]. For instance infants, 
children, and preadolescents born preterm were found 
to exhibit altered development in the cerebellum and 
reduced cerebellar volume [102]; reduced white matter 
integrity [103]; as well as significant deficits in executive 
function and memory [104].
Animal studies
Animal studies are in accordance with the above-men-
tioned clinical findings whereby full thickness skin 
removal (wound of 2 mm in diameter) in rats performed 
at birth results in hyperinnervation of the wounded 
area that persist long after the wound has healed (i.e. up 
to 12  weeks). This hyperinnervation involved both Aδ 
and C-fibers and paralleled a decrease in the threshold 
to mechanical stimuli applied to the injured area [105]. 
Neonatal hindpaw injury produces hyperalgesia in adult-
hood [20] and intrathecal administration of minocycline, 
which inhibits microglial activity, at the time of adult 
insult prevent this hyperalgesia [106]. Finally, adult rats 
treated with the persistent inflammatory-inducing agent, 
Compound Freund Adjuvant (CFA), at PND 1 displayed 
increased density of dorsal horn nociceptive primary 
afferents [107]. And electrophysiological recording of 
dorsal horn neuron from adult rats treated with CFA as 
neonates revealed enhanced evoked responses to brush 
and noxious pinch compared to untreated rats [107].
The mechanisms underlying the hyperalgesia following 
early life adverse events are numerous. The hyperalgesia 
can be mediated by peripheral nerve sprouting such as 
the innervation of nociceptors is increased as previously 
confirmed [89]. Also, the ensuing inflammation may con-
tribute to enhanced dorsal horn central sensitization as 
Ruda et  al. previously reported [107]. Furthermore, the 
hyperalgesia can result from altered descending inhibi-
tory control systems and decreased opioidergic drive 
in the PAG. Finally and of particular importance to this 
review the altered pain responses can result from altered 
neuroimmune responses as described below.
Neuroimmune interface in pain
Traditionally implicated in defending the organism 
against microbial pathogens or “non-self”, the immune 
system is now well appreciated to play a critical role in 
pain modulation [108–110]. Following injury, immune 
cells release proinflammatory cytokines and other inflam-
matory molecules such as histamine, prostaglandins, 
eicosanoids and cytokines that sensitize nociceptors. For 
instance, nociceptors are known to be interleukin (IL)-
1-β sensors and IL-1-β can directly activate nociceptors 
to generate action potentials and induce hyperalgesia 
[111]. Moreover, intraplantar injection of IL-1-β increase 
the discharge of spinal dorsal horn neurons to thermal 
and mechanical stimuli [112]. The contribution to pain 
hypersensitivity can be mediated by inflammatory medi-
ators released by immune cells but also by immune cells 
infiltration per se. The release of cytokines contributes 
to the recruitment of granulocytes, monocytes and mast 
cells at the site of inflammation. An increasing body of 
evidence suggests that infiltration by macrophages and 
T-cells in the dorsal root ganglia following nerve injury 
[113, 114] as well as activation of microglial cells in the 
spinal cord that coincides with enhanced neuropathic 
pain [115]. Hyperalgesia following nerve injury is sub-
stantially reduced in mice lacking T cells [116–118] and 
following the inhibition of microglia by minocycline 
[119]. Infiltration of immune cells at the peripheral level 
is also important in contributing to pain modulation. Fol-
lowing injury, mast cells are first to infiltrate the site of 
inflammation and they can degranulate within minutes 
of inflammation leading to the release of histamine, pros-
taglandin, bradykinin and other inflammatory markers 
that participate in the vasodilation and nociceptors sen-
sitization [120]. Interestingly, mast cell degranulation 
requires direct contact with nociceptors via molecule of 
adhesion (N-cadherin) [121]. In our laboratory, we have 
demonstrated that neonatal exposure to the bacterial 
mimetic lipopolysaccharide (LPS) produced hyperalge-
sia in preadolescent rats that coincided with enhanced 
mast cell degranulation [23]. In a recent clinical study, Di 
Nardo et  al. showed that children suffering from Irrita-
ble Bowel Syndrome (IBS) exhibit an increased number 
of mast cells in the proximity to nerves in the ileal and 
colonic mucosa [122]. More importantly, the intensity of 
abdominal pain reported by these children was signifi-
cantly correlated to the close proximity of mast cells to 
nerve endings in the gut wall [122].
Other events that can contribute to the induction of 
the immune system are exposure to viruses, lipopoly-
saccharide (LPS), cell wall of gram-negative bacteria, 
or fungal infections during both the neonatal and adult 
life. When exposed to such components, immune cells 
including monocytes, lymphocytes, leukocytes, mac-
rophages, T cells and mast cells not only signal other 
components of the immune system (i.e. complement) but 
also the brain [123] to control the inflammatory response 
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and to maintain it at homeostatic levels. This is made 
possible by the release of a plethora of pro-inflammatory 
cytokines including IL-1-β [124], IL-6 [125], IL-8 [126], 
IL-12 [127], interferon-α (IFN-α) and -δ (IFN-δ) [128] as 
well as tumor necrosis factor (TNF)-α [129, 130]. Since 
cytokines are large molecules that are unlikely to cross 
the blood brain barrier (BBB) [131], it has been pos-
tulated that they can act on the brain through different 
pathways. For instance, via the synthesis of prostaglandin 
E2 by brain microvessel endothelial cells [132]. Another 
possibility is through vagal afferences as subdiaphrag-
matic lesions of the visceral vagal afferents terminating in 
the nucleus tractus solitaris abolished the LPS or IL-1β-
induced hyperalgesia [133]. Subdiaphragmatic lesions of 
the vagus nerve also abolishes expression of Fos-protein 
in the secondary projections of this nerve such as the 
paraventricular nucleus of the hypothalamus (PVN), cen-
tral nucleus of the amygdala (CeA), and the bed nucleus 
of the stria terminalis following IP injection of LPS [134]. 
This indicates that systemic LPS requires an intact func-
tional vagus nerve to induce neuronal activation of brain 
regions involved in neuroendocrine function such as 
the PVN. It has also been suggested that cytokines can 
reach the brain via areas devoid of BBB such as the orga-
num vasculosum lamina terminalis (OVLT) [135] or the 
macrophage-like cells commonly known as circumven-
tricular organs [136]. The brain production of IL-1β fol-
lowing peripheral inflammatory stimuli such as in the 
case of LPS administration can be first restricted to cho-
roid plexus and circumventricular organs, and then to 
the brain side of the BBB by slow diffusion (via volume 
transmission) [137]. Finally cytokines can reach the brain 
through a saturable transport system, which although 
has been demonstrated to exist in mice but not rats [138, 
139], its physiological relevance remains unclear.
All of these neuroimmune pathways ultimately lead 
to the production of cytokines by brain microglia and 
induce a set of physiological responses commonly known 
as “sickness behavior”, which include fever, malaise, leth-
argy, decreased appetite and libido [123, 140]. The sick-
ness response is an adaptive mechanism assisting in the 
recovery process from acute viral/bacterial infections. 
For instance fever, induced by the action of the pyrogenic 
IL-1 on anterior hypothalamus, elevates the body’s tem-
perature to assist the immune system in fighting infec-
tions by blocking the growth of microorganisms [141]. 
Fatigue helps conserve energy so much needed in order 
to fight infection. However, in some circumstances, this 
process can go seriously wrong such as in the case of 
uncontrolled, exaggerated and prolonged inflammatory 
response in the CNS. This maladaptive response can be 
exemplified in clinical settings of post-infectious chronic 
fatigue syndrome [142], irritable bowel syndrome [143], 
or post-viral depression [144]. Importantly, pain facilita-
tion or hyperalgesia is also considered to be an integral 
part of sickness behavior [145, 146]. Proinflammatory 
cytokines released by immune cells are known to induce 
hyperalgesia when administered at the peripheral or 
central level. Among the many types of pro-inflamma-
tory cytokines, IL-1β is the most characterized potent 
mechanical and thermal hyperalgesic agent when injected 
into peripheral tissue or the CNS [112, 133, 147, 148]. For 
instance, intracerebroventricular (ICV) injection of the 
recombinant human IL-1β (rhIL-1β) in rats significantly 
decreased paw lick latency to thermal noxious stimulus 
[148]. This thermal hyperalgesia was abolished by ICV 
administration of the IL-1β antagonist IL-1ra [148]. In 
our laboratory, we have demonstrated increased forma-
lin-induced behavioural responses in LPS-treated adult 
rats that paralleled enhanced circulating IL-1β 1-h fol-
lowing formalin injection [23]. Additionally, adult rats 
treated with LPS at PND 3 and 5 displayed increased 
IL-1β in the hippocampus 1  h following formalin injec-
tion, an effect that coincided the increased formalin-
induced nociception observed in adult LPS-treated rats. 
The neurocircuitry underlying central action of cytokines 
is not only restricted to the brain but can also involve the 
spinal cord by increasing the excitability of spinal dorsal 
horn neurons [149, 150]. As discussed previously, activa-
tion of microglia at the spinal level plays a critical role in 
producing this cytokine-induced hyperalgesia [151].
The impact of neonatal and adult LPS exposure 
on pain responses
Neonatal or adult exposure to the bacterial mimetic has 
been reported in both clinical and animal studies to pro-
duce increased pain sensitivity later in life. Boisse L et al. 
were the first to report that rats administered with LPS 
at PND 14 exhibited a significant decrease in withdrawal 
latency to thermal and mechanical stimuli in adulthood 
[152]. These adult rats displayed allodynia (a stimu-
lus that is normally not painful is perceived as painful) 
and hyperalgesia (exaggerated responses to stimuli) in 
both tests of thermal (i.e. hot-plate test) and mechani-
cal nociception (i.e. Von Frey test). Of particular interest, 
no significant differences were observed in nociceptive 
responses when a second LPS injection was administered 
in adulthood. This implies that a single LPS administra-
tion is enough to produce long-term alterations in nocic-
eptive responses. Moreover, the thermal and mechanical 
hyperalgesia in neonatally LPS-treated rats was associated 
with upregulation of COX-2 protein level in the spinal 
cord [152], suggesting a potential role of prostaglandins 
in the hyperexcitability of spinal dorsal horn neurons in 
LPS-treated rats. We have replicated these findings such 
that rats exposed to LPS during PND 3 and 5 displayed 
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increased formalin-induced nociceptive responses (i.e. 
flinching and licking) following formalin injection at PND 
22 and PND 80–97 but not PND 7 or PND 13 [10, 23, 
24]. This LPS-induced hyperalgesia was accompanied by 
peripheral and central neuroimmune and neuroendocrine 
changes as well as altered spinal and supraspinal neuronal 
responses [10, 23, 24]. More recently Hunter D and col-
leagues reconfirmed these findings showing that at 4  h 
and 8 h post LPS administration, PND 21 rats (PND0 as 
birth) displayed enhanced formalin-induced nociception 
during the late phase [153]. Adult LPS administration in 
rats is also reported to significantly decrease the tail-flick 
latency, which starts within few minutes of LPS injection 
and lasts for 60 min [154]. The LPS-induced hyperalgesia 
can be blocked following administration of IL1-ra, sug-
gesting a critical role of IL-1 in inducing the LPS-induced 
hyperalgesia [155]. These animal studies are consistent 
with clinical findings showing that humans subjected to 
an IV injection of LPS exhibited enhanced flare, hyperal-
gesia, and allodynia in response to capsaicin administra-
tion [156] as well as lower pressure pain thresholds that 
correlated with enhanced circulating levels of IL-6 and 
TNF-α, an effect more pronounced in women [157]. This 
is consistent with a recent study, which demonstrated that 
IV injection of LPS produced a significant decrease in rec-
tal and pressure pain thresholds [158]. This LPS-induced 
visceral hyperalgesia was accompanied by a significant 
increase in circulating pro-inflammatory cytokines as 
indicated by a peak of TNFα and IL6 1 and 2 h (respec-
tively) following LPS administration [159].
Taken together, these animal and clinical findings sug-
gest that far from the traditional view that posits that 
pain can solely be attributed to activation of neurons, the 
immune system via peripheral and central release of pro-
inflammatory cytokines contribute significantly to pain 
modulation. Integrating the neuroimmune interface in 
pain modulation is thus a necessary step in order to find 
efficient treatments to treat chronic pain.
Neuroendocrine‑immune crosstalk: Focus on IL‑1β 
and implications for pain
During the late 80s, a series of elegant studies mainly car-
ried out by Sapolsky and Besedovsky group have demon-
strated that components of the immune system, namely 
cytokines and in particular IL-1β can directly activate the 
HPA axis leading to the release of glucocorticoids [160, 
161]. In a clinical study on post-mortem tissue, immuno-
histochemistry staining using antiserum directed against 
human IL-1β revealed that the human hypothalamus is 
densely innervated by IL-1β fibers [161]. The densest inner-
vations were found in the periventricular region that con-
trols the anterior pituitary. IL-1β-immunoreactive fibers 
were also found in the arcuate nuclei and parvocellular part 
of the paraventricular nucleus [161]. In rats, intravenous 
injection of IL-1β induced cfos expression in corticotro-
pin-releasing hormone (CRH) containing neurons in the 
paraventricular nucleus of the hypothalamus (PVN) [162]. 
Systemic or intracerebroventricular injection of IL-1β 
also induced the release of circulating corticosterone and 
adrenocorticotropic hormone (ACTH) [163, 164]. Moreo-
ver, immunoneutralization of IL-1β or CRH blocked the 
stimulatory effect of IL-1β on ACTH [164]. This response 
is primarily mediated by the release of CRH from the PVN 
[164]. Additionally, IL-1β has been reported to act directly 
on the anterior pituitary cells to release ACTH [165].
Adrenocorticoids such as cortisol in humans and corti-
costerone in rats are known for their immunosuppressive 
function [166]. However their exact contribution to pain 
modulation is still not clear and literature regarding the 
role of glucocorticoids in modulating pain is at best con-
flicting. It is not surprising that glucocorticoids play an 
important role in pain modulation since pain is an aversive 
stressful event and hence capable of activating the HPA 
axis. Whilst several clinical studies have reported hypo-
cortisolemia in patients with fibromyalgia and chronic low 
back pain [167–169], others have found that corticoster-
one reduces the inflammation associated with pain [170, 
171]. In our laboratory, we demonstrated that neonatal 
LPS exposure produced a developmentally regulated acti-
vation of HPA axis activity following a noxious stimulus 
(i.e. formalin injection) as indicated by increased plasma 
levels of corticosterone in PND 13 and 22 but not PND 7 
rats [10]. Preadolescent rats neonatally treated with LPS 
also exhibited decreased GR mRNA transcripts in the 
hypothalamus compared to rats that had saline during the 
neonatal period [10]. This is in agreement with previous 
studies indicating that noxious stimuli including formalin 
injection are capable of activating the HPA axis [172–174]. 
These findings indicate that the relationships between 
peripheral HPA axis activity and pain modulation is com-
plex. Further studies investigating the exact contribution 
of the HPA axis in pain modulation are needed.
Conclusion and final remarks
As human beings, our organism is very complex. Far 
from the traditional view that posits that every physi-
ological system is self-regulated, every physiological 
system including the immune, endocrine, and nervous 
system are interconnected via well-organized and harmo-
nious regulatory mechanisms. In fact, dysfunction in one 
physiological system will lead to dysfunction of another. 
The immune system communicates with the endocrine 
and nervous systems mainly via cytokines which can act 
directly on the brain to produce local neuroinflammation 
but also exert a direct action on the HPA axis to produce 
the release of cortisol. Given that the immune, endocrine, 
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and nervous systems undergo significant plasticity dur-
ing the perinatal period, exposure to adverse events dur-
ing this critical window of development is susceptible 
to disturb the normal developmental trajectory of these 
systems and consequently disturb the highly organized 
neuroendocrine to immune network leading to long-
term consequences including altered pain responses. 
The challenge now facing the scientific community and 
clinicians is how to translate the well-established con-
cept of psychoneuroimmunology and psychoneuroen-
docrinology as well as the importance of early life events 
in programming future pain responses into therapeutic 
approaches to treat chronic pain. Instead of the reduc-
tionist approach, which consists of targeting neurons 
only, we can also target components of the endocrine 
system such as corticosterone blockers or components 
of the immune system such as blocking the inflammatory 
process via suppressing the activity of pro-inflammatory 
cytokines or enhancing the activity of anti-inflammatory 
cytokines (Fig. 2).
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